Clinical data | |
---|---|
Trade names | Revanex[1] |
Other names | YH1885 |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C22H23FN4 |
Molar mass | 362.452 g·mol−1 |
3D model (JSmol) | |
| |
|
Revaprazan (trade name Revanex) is a drug that reduces gastric acid secretion which is used for the treatment of gastritis.[2] It acts as an acid pump antagonist[3] (potassium-competitive acid blocker). Revaprazan is approved for use in South Korea,[4] but is not approved in Europe or the United States.